A 12-month double-blind sham-surgery-controlled trial assessing adeno-associated virus type 2 ( AAV2 ) - neurturin injected into the putamen bilaterally failed to meet its primary endpoint , but showed positive results for the primary endpoint in the subgroup of subjects followed for 18 months and for several secondary endpoints .